Ajanta Pharma Share: Analyst ne bola 'Reduce', target ₹2,760! Kya ho raha hai?

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAarav Shah|Published at:
Ajanta Pharma Share: Analyst ne bola 'Reduce', target ₹2,760! Kya ho raha hai?
Overview

Lo bhai, Ajanta Pharma ke liye brokerage Choice Equities ne bola hai ki abhi 'Reduce' karne ka time hai. Unhone target price thoda badha kar **₹2,760** kar diya hai, par stock pe nazar rakhni padegi.

Margin Pressure Aur Investment Ka Game

Ajanta Pharma filhaal kaafi heavy investment kar rahi hai apne sales force ko expand karne mein aur brands ko strong banane mein. Is wajah se unke EBITDA margins lagbhag 27% par hi ruke hue hain. Analyst logon ko lagta hai ki jab tak Asian markets recover nahi hote aur company apne naye products ko successful nahi bana leti, tab tak margins mein badi improvement nahi dikhegi. Haalanki, Q3 FY26 mein company ka revenue 20% saal-dar-saal badhkar ₹1,375 crore ho gaya hai aur net profit 17.6% badhkar ₹274 crore ho gaya hai. India aur US markets se revenue growth achhi mil rahi hai.

Future Ka Plan: Semaglutide Launch!

Sabse badi khabar ye hai ki March 2026 tak company Semaglutide launch karne ki planning kar rahi hai. Yeh medium term mein growth ka bada driver ban sakta hai, kyunki Indian semaglutide market 17.8% CAGR se badhne ka estimate hai. Lekin, is launch ko execute karne mein thode risks bhi hain jin par investors ko dhyaan dena hoga.

Analyst Ka View Aur Valuation

Choice Institutional Equities ne is sab ko dekh kar apne FY27 estimates ko 8.8% tak badha diya hai. Par unka kehna hai ki stock ka current valuation already kaafi growth dikha raha hai. Isliye unhone 'Reduce' rating maintain rakhi hai aur target price ko ₹2,760 set kiya hai. Stock abhi ₹2,778 ke aas paas trade kar raha hai, jo analyst ke target price ke kareeb hi hai. Company ka P/E ratio 34.7x hai, jo uske historical average 26-28x se kaafi upar hai. Yeh sab factors milakar analyst thoda cautious hain, khaas kar Semaglutide market mein competition aur execution risks ko dekhte hue.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.